ArticleFrontiers in oncology2025
Home-Combo: an online home-based exercise intervention for women with breast cancer undergoing neoadjuvant chemotherapy: study protocol for a 2-arm pragmatic randomized controlled trial.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06429189 (An Online Home-based Combined Exercise Intervention With Self-selected Intensity for Women With Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Online Home-based Combined Exercise Intervention With Self-selected Intensity for Women With Breast Cancer: The Home-Combo Randomized Controlled Trial.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy carry side effects and potentially result in dose decreases or treatment delays of women with breast cancer (BC). Relative dose intensities of chemotherapy <85% are associated with a worse disease prognosis and lower treatment efficacy. Exercise may modulate treatment response through its effects on tumor microenvironment. Home-based exercise is a convenient strategy, proven to be effective and beneficial for women with a BC diagnosis under treatment. Recent evidence suggests that exercise may contribute to tumor regression neoadjuvant treatment. Studies investigating the effects of exercise interventions on chemotherapy completion rates are needed. No study appears to have analyzed the effects of a home-based exercise interventions on tumor regression in women with BC. This paper describes the protocol of a 2-arm pragmatic randomized controlled trial, targeting women with a BC undergoing neoadjuvant chemotherapy. Methods: A 2-arm randomized controlled trial implemented in a real-world exercise setting to compare an online structured and supervised group exercise intervention, with an active control group, during the neoadjuvant chemotherapy phase. Ninety-eight participants with a BC diagnosis stage I-III, scheduled to have neoadjuvant chemotherapy will be enrolled continuously for one year. The primary outcomes of this study will be chemotherapy completion rate and tumor regression. Secondary outcomes will include, body composition, functional performance, and self-reported physical activity levels and general and BC-specific quality of life. Outcome measures will be obtained at baseline, mid-treatment, post-intervention, and 3-month follow-up. Discussion: Home-based exercise training programs are safe for women with BC during the treatment. Studies conducting structured and supervised home-based exercise programs in women with BC during the treatment are still scarce. Since this study involves participants performing neo-adjuvant chemotherapy, it will allow to verify the effects of the intervention in a prehabilitation context and analyze its effects on the post-surgery recovery of the participants in the follow-up assessment. More studies analyzing the effects of exercise on chemotherapy completion rates and tumor regression in BC are needed. The study results may represent less time to treatment exposure, quicker return to everyday life, fewer side effects, and better overall and disease-related quality of life. Clinical Trial Registration: clinicaltrials.gov, identifier NCT06429189.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.